SCHEMBL20239245

SCHEMBL20239245

CNc1nc(CNc2ncc(Cl)cn2)cc(Oc2ccc(CS(N)(=O)=O)cc2)n1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT2 Q96PD7 1/20 0.69
CA1 P00915 2/20 0.37
CA2 P00918 2/20 0.37
CA9 Q16790 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.35
ALDH1A1 P00352 2/20 0.34
RAB9A P51151 1/20 0.34
GPR39 O43194 1/20 0.34
VNN1 O95497 1/20 0.34
PDE4B Q07343 2/20 0.33
MET P08581 1/20 0.33
KDR P35968 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 3/20 0.33
CYP1A2 P05177 2/20 0.33
CYP2C19 P33261 2/20 0.33
KDM4E B2RXH2 2/20 0.33
MAPT P10636 1/20 0.33
LMNA P02545 1/20 0.32
GLA P06280 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16746061 0.89 DGAT2 (0.70) DGAT2CA1CA2CA9SMN1; SMN2
SCHEMBL20239204 0.88 DGAT2 (0.69) DGAT2CA1CA2CA9SMN1; SMN2
SCHEMBL20239257 0.87 DGAT2 (0.67) DGAT2CA1CA2CA9SMN1; SMN2
SCHEMBL20239246 0.84 DGAT2 (0.50) DGAT2SMN1; SMN2RAB9AGPR39MET
SCHEMBL20239260 0.82 DGAT2 (0.46) DGAT2CA1CA2CA9SMN1; SMN2
SCHEMBL20239199 0.82 DGAT2 (1.00) DGAT2CA1CA2CA9
SCHEMBL20239203 0.82 DGAT2 (0.59) DGAT2SMN1; SMN2ALDH1A1RAB9AVNN1
SCHEMBL20239319 0.81 DGAT2 (0.60) DGAT2CA1CA2CA9SMN1; SMN2
SCHEMBL20239312 0.81 DGAT2 (0.47) DGAT2CA1CA2CA9SMN1; SMN2
SCHEMBL16738674 0.80 DGAT2 (0.57) DGAT2SMN1; SMN2ALDH1A1RAB9AVNN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3298001-B1 DGAT2 INHIBITORS LILLY CO ELI (US) 2020-05-13 EP disclosed
US-10053429-B2 DGAT2 inhibitors ELI LILLY AND COMPANY (US) 2018-08-21 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162825-A1 NOVEL DGAT2 INHIBITORS DGAT2, DGAT1, LCAT DGAT2 1/4885CA1 4849/4885CA2 4773/4885
US-10053429-B2 DGAT2 inhibitors DGAT2, DGAT1, LCAT DGAT2 1/4885CA1 4830/4885CA2 4742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.